GH Research (NASDAQ:GHRS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of GH Research (NASDAQ:GHRS – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

A number of other research firms have also weighed in on GHRS. New Street Research set a $65.00 target price on shares of GH Research in a report on Monday, August 10th. Wells Fargo & Company began coverage on shares of GH Research in a research note on Monday, July 27th. They issued an “overweight” rating and a $44.00 target price on the stock. Needham & Company LLC raised their price target on shares of GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Stifel Nicolaus set a $38.00 price target on shares of GH Research in a research report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of GH Research in a report on Monday, August 10th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, GH Research has an average rating of “Moderate Buy” and an average price target of $44.36.

Read Our Latest Analysis on GHRS

GH Research Stock Down 1.8%

Shares of GHRS opened at $18.75 on Friday. The business’s 50-day moving average price is $22.11 and its 200-day moving average price is $21.65. GH Research has a twelve month low of $12.04 and a twelve month high of $31.44. The stock has a market cap of $1.29 billion, a PE ratio of -19.74 and a beta of 1.31.

GH Research (NASDAQ:GHRS – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13. Analysts expect that GH Research will post -1.20 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its position in shares of GH Research by 43.1% in the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after purchasing an additional 780 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in GH Research during the third quarter valued at approximately $82,000. China Universal Asset Management Co. Ltd. lifted its position in GH Research by 30.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company’s stock valued at $432,000 after purchasing an additional 4,106 shares during the last quarter. Bellevue Group AG bought a new stake in GH Research during the third quarter valued at approximately $109,000. Finally, Farther Finance Advisors LLC grew its stake in GH Research by 9,720.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock worth $231,000 after buying an additional 9,720 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

(Get Free Report)

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.

Further Reading

Analyst Recommendations for GH Research (NASDAQ:GHRS)

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.